EP4719480A1 - Ligands de peptides bicycliques spécifiques d'epha2 et utilisations associées - Google Patents

Ligands de peptides bicycliques spécifiques d'epha2 et utilisations associées

Info

Publication number
EP4719480A1
EP4719480A1 EP24732758.8A EP24732758A EP4719480A1 EP 4719480 A1 EP4719480 A1 EP 4719480A1 EP 24732758 A EP24732758 A EP 24732758A EP 4719480 A1 EP4719480 A1 EP 4719480A1
Authority
EP
European Patent Office
Prior art keywords
dose
patient
cancer
pharmaceutical composition
epha2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP24732758.8A
Other languages
German (de)
English (en)
Inventor
Gavin Bennett
Hanna ORR
Paola PAGANONI
Assunta DE RIENZO
Carly CAMPBELL
Qin TJOKROSURJO
Mengyao LI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BicycleTx Ltd
Original Assignee
BicycleTx Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2023/067777 external-priority patent/WO2024248860A1/fr
Application filed by BicycleTx Ltd filed Critical BicycleTx Ltd
Publication of EP4719480A1 publication Critical patent/EP4719480A1/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne un conjugué de toxine bicyclique BT5528, des sels pharmaceutiquement acceptables de celui-ci ou des compositions pharmaceutiques de celui-ci, ainsi que leurs utilisations.
EP24732758.8A 2023-06-01 2024-05-31 Ligands de peptides bicycliques spécifiques d'epha2 et utilisations associées Pending EP4719480A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/US2023/067777 WO2024248860A1 (fr) 2023-06-01 2023-06-01 Ligands de peptides bicycliques spécifiques d'epha2 et utilisations associées
US202363609655P 2023-12-13 2023-12-13
PCT/GB2024/051423 WO2024246551A1 (fr) 2023-06-01 2024-05-31 Ligands de peptides bicycliques spécifiques d'epha2 et utilisations associées

Publications (1)

Publication Number Publication Date
EP4719480A1 true EP4719480A1 (fr) 2026-04-08

Family

ID=91530249

Family Applications (1)

Application Number Title Priority Date Filing Date
EP24732758.8A Pending EP4719480A1 (fr) 2023-06-01 2024-05-31 Ligands de peptides bicycliques spécifiques d'epha2 et utilisations associées

Country Status (6)

Country Link
EP (1) EP4719480A1 (fr)
JP (1) JP2026523407A (fr)
CN (1) CN121889170A (fr)
AU (1) AU2024279019A1 (fr)
IL (1) IL324830A (fr)
WO (1) WO2024246551A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119874840B (zh) * 2025-03-31 2025-08-08 晶核生物医药科技(上海)有限公司 一种双环肽及其应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6074574B2 (ja) 2008-02-05 2017-02-08 バイシクル セラピューティクス リミテッド 方法及び組成物
CN114760988A (zh) * 2019-11-27 2022-07-15 拜斯科技术开发有限公司 对EphA2具有特异性的双环肽配体和其用途

Also Published As

Publication number Publication date
CN121889170A (zh) 2026-04-17
IL324830A (en) 2026-01-01
WO2024246551A1 (fr) 2024-12-05
AU2024279019A1 (en) 2025-12-18
JP2026523407A (ja) 2026-07-14

Similar Documents

Publication Publication Date Title
WO2021234391A1 (fr) Ligands peptidiques bicycliques spécifiques de la nectine 4 et leurs utilisations
EP4065085A1 (fr) Ligands de peptides bicycliques spécifiques de epha2 et utilisations associées
JP2024543505A (ja) 癌の治療方法
US20160184453A1 (en) Carrier-Antibody Compositions and Methods of Making and Using the Same
KR20250056270A (ko) 활성화 fgfr3 유전자 변화를 갖는 고형 종양을 치료하는 방법
MD3393478T2 (ro) Terapie combinată
AU2024279019A1 (en) BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR EphA2 AND USES THEREOF
AU2024279075A1 (en) Bicyclic peptide ligands specific for nectin-4 and uses thereof
WO2024248859A1 (fr) Ligands peptidiques bicycliques spécifiques de la nectine 4 et leurs utilisations
AU2023449926A1 (en) Bicyclic peptide ligands specific for epha2 and uses thereof
AU2024342769A1 (en) Bicyclic peptide ligands specific for nectin-4 and uses thereof
WO2023136837A1 (fr) Utilisation de tivozanib et de durvalumab pour le traitement du carcinome hépatocellulaire (hcc)
WO2025125809A1 (fr) Ligands peptidiques bicycliques spécifiques de la nectine-4 et leurs utilisations
EA047123B1 (ru) Бициклические пептидные лиганды, специфические для нектина-4, и их применение
WO2025125648A1 (fr) Complexe peptidique bicyclique destiné à être utilisé dans le traitement du cancer
WO2025260061A1 (fr) Compositions et méthodes de thérapie anticancéreuse
CN121843713A (zh) 使用抗pd-1和化学疗法治疗肺癌
KR20250069903A (ko) 암 치료를 위한 B-Raf 저해제와 항-EGFR 항체의 조합물
EA043796B1 (ru) Лечение гепатоцеллюлярной карциномы, которая характеризуется вирусной инфекцией гепатита b

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20251215

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR

P01 Opt-out of the competence of the unified patent court (upc) registered

Free format text: CASE NUMBER: UPC_APP_0012231_4719480/2026

Effective date: 20260409

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40134396

Country of ref document: HK